<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37794541</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1119-3077</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nigerian journal of clinical practice</Title><ISOAbbreviation>Niger J Clin Pract</ISOAbbreviation></Journal><ArticleTitle>The utility of CONUT score in indolent lymphoma patients.</ArticleTitle><Pagination><StartPage>1290</StartPage><EndPage>1296</EndPage><MedlinePgn>1290-1296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/njcp.njcp_20_23</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="UNASSIGNED">Similar to the uncertainties in the treatment criteria for indolent non-Hodgkin lymphoma (iNHL), the prognostic criteria have not been fully clarified. The Controlled Nutritional Status (CONUT) score is not only used as a predictor of malnutrition but also indicates prognosis in many chronic or malignant diseases. The aim of this study is to investigate the predictive and prognostic significance of the CONUT score in patients with iNHL.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">A retrospective evaluation was made of 109 patients with iNHL. The CONUT scores of the patients were compared between those with an indication for treatment and those followed without treatment. The same analysis was performed between patients who developed relapse after treatment. Survival analysis was performed on all patients, and associations between survival and the CONUT score were examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The median CONUT score was found to be higher in those who had treatment indications compared to those who did not (2 vs 1; P = 0.014). In the regression model, a CONUT absolute value above 5 was found as an independent risk factor predicting relapse. In the whole study population, a CONUT absolute value &gt;2 predicted the risk of mortality with 53.9% sensitivity and 68.7% specificity (AUC &#xb1; SE = 0.639 &#xb1; 0.07; +PV = 35%; -PV = 82.6%; P = 0.034).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">CONUT score is a predictive and prognostic factor for patients with iNHL. The development of simple, low-budget prognostic and predictive biomarkers is critical not only for determining the course of the disease but also for follow-up and treatment management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tiglioglu</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dr. Ers&#x131;n Arslan Tra&#x131;n&#x131;ng and Research Hosp&#x131;tal, Hematology, Gaz&#x131;antep, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A &#xd6;zt&#xfc;rk</LastName><ForeName>H B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Ankara C&#x131;ty Hosp&#x131;tal, Hematology, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Y&#x131;ld&#x131;z</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>H&#x131;t&#x131;t Un&#x131;vers&#x131;ty, Hematology, Corum, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#x131;&#x11f;l&#x131;o&#x11f;lu</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dr. Ers&#x131;n Arslan Tra&#x131;n&#x131;ng and Research Hosp&#x131;tal, Hematology, Gaz&#x131;antep, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Y&#x131;lmaz</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ankara C&#x131;ty Hosp&#x131;tal, Hematology, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aras</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Ankara C&#x131;ty Hosp&#x131;tal, Hematology, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albayrak</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Health Sciences Diskapi Yildirim Beyazit Education and Research Hospital, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Niger J Clin Pract</MedlineTA><NlmUniqueID>101150032</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CONUT score</Keyword><Keyword MajorTopicYN="N">indolent lymphomas</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37794541</ArticleId><ArticleId IdType="doi">10.4103/njcp.njcp_20_23</ArticleId><ArticleId IdType="pii">NigerJClinPract_2023_26_9_1290_386235</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>